The ARVs result in constitutive activation of the AR pathway thereby promoting prostate cancer (PC) cell growth at low concentrations of androgens [4, 6], enhance growth of androgen dependent xenografts in castrated mice [3] and the development of enzalutamide resistant PC [7]. The gene discussed is AR; the disease is pachyonychia congenita.